Alcon, the Fort Worth, Texas-based eye care division of healthcare products company Novartis, has announced that it has received European clearance for JETREA.
Alcon received the rights to market JETREA, an injectable treatment of vitreomacular traction, in the US in October 2012.
More Articles on Ophthalmology:
EyeTechCare Receives $13M in Funding
10 Statistics on Ophthalmologist Compensation by Location
Flaum Eye Institute Recruits Dr. Harold Ross
Alcon received the rights to market JETREA, an injectable treatment of vitreomacular traction, in the US in October 2012.
More Articles on Ophthalmology:
EyeTechCare Receives $13M in Funding
10 Statistics on Ophthalmologist Compensation by Location
Flaum Eye Institute Recruits Dr. Harold Ross